uniQure N.V. (QURE)
QURE Stock Price Chart
Explore uniQure N.V. interactive price chart. Choose custom timeframes to analyze QURE price movements and trends.
QURE Company Profile
Discover essential business fundamentals and corporate details for uniQure N.V. (QURE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Feb 2014
Employees
209.00
Website
https://www.uniqure.comCEO
Matthew Craig Kapusta CPA
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
QURE Financial Timeline
Browse a chronological timeline of uniQure N.V. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 4 Nov 2025
EPS estimate is -$0.87.
Earnings released on 29 Jul 2025
EPS came in at -$0.69 surpassing the estimated -$0.89 by +22.47%, while revenue for the quarter reached $5.26M , beating expectations by +11.32%.
Earnings released on 9 May 2025
EPS came in at -$0.82 surpassing the estimated -$1.07 by +23.36%, while revenue for the quarter reached $1.57M , missing expectations by -73.43%.
Earnings released on 27 Feb 2025
EPS came in at -$1.50 falling short of the estimated -$0.60 by -150.00%, while revenue for the quarter reached $5.22M , missing expectations by -71.69%.
Earnings released on 5 Nov 2024
EPS came in at -$0.91 surpassing the estimated -$1.12 by +18.75%, while revenue for the quarter reached $2.29M , missing expectations by -87.52%.
Earnings released on 1 Aug 2024
EPS came in at -$1.16 surpassing the estimated -$1.24 by +6.45%, while revenue for the quarter reached $11.13M , beating expectations by +63.86%.
Earnings released on 7 May 2024
EPS came in at -$1.36 falling short of the estimated -$1.31 by -3.82%, while revenue for the quarter reached $8.49M , beating expectations by +36.20%.
Earnings released on 28 Feb 2024
EPS came in at -$1.53 surpassing the estimated -$1.54 by +0.65%, while revenue for the quarter reached $6.69M , beating expectations by +19.66%.
Earnings released on 7 Nov 2023
EPS came in at -$1.88 falling short of the estimated -$1.49 by -26.17%, while revenue for the quarter reached $1.41M , missing expectations by -76.97%.
Earnings released on 1 Aug 2023
EPS came in at -$1.44 falling short of the estimated $2.97 by -148.48%, while revenue for the quarter reached $2.42M , missing expectations by -98.83%.
Earnings released on 9 May 2023
EPS came in at -$1.63 falling short of the estimated -$1.02 by -59.80%, while revenue for the quarter reached $5.33M , missing expectations by -81.15%.
Earnings released on 27 Feb 2023
EPS came in at $0.15 surpassing the estimated -$0.89 by +116.85%, while revenue for the quarter reached $102.75M , beating expectations by +429.18%.
Earnings released on 2 Nov 2022
EPS came in at -$1.02 surpassing the estimated -$1.11 by +8.11%, while revenue for the quarter reached $1.45M , missing expectations by -58.40%.
Earnings released on 8 Aug 2022
EPS came in at -$0.84 surpassing the estimated -$0.96 by +12.50%, while revenue for the quarter reached $497.00K , missing expectations by -95.12%.
Earnings released on 2 May 2022
EPS came in at -$1.00 falling short of the estimated -$0.67 by -49.25%, while revenue for the quarter reached $1.79M , missing expectations by -89.85%.
Earnings released on 25 Feb 2022
EPS came in at $0.17 surpassing the estimated -$0.81 by +120.99%, while revenue for the quarter reached $57.69M , beating expectations by +436.84%.
Earnings released on 25 Oct 2021
EPS came in at -$0.79 surpassing the estimated -$1.00 by +21.00%, while revenue for the quarter reached $1.99M , missing expectations by -21.07%.
Earnings released on 26 Jul 2021
EPS came in at $8.51 surpassing the estimated $2.96 by +187.50%, while revenue for the quarter reached $463.87M , beating expectations by +18.31K%.
Earnings released on 10 May 2021
EPS came in at -$0.91 falling short of the estimated -$0.89 by -2.25%, while revenue for the quarter reached $454.00K , beating expectations by +3.53%.
Earnings released on 1 Mar 2021
EPS came in at -$0.01 surpassing the estimated -$0.78 by +98.72%, while revenue for the quarter reached $34.09M .
Earnings released on 27 Oct 2020
EPS came in at -$1.21 falling short of the estimated $1.70 by -171.18%, while revenue for the quarter reached $1.79M , missing expectations by -33.15%.
QURE Stock Performance
Access detailed QURE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.